13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • CS1001-101

    Acronym: 

    CS1001-101

    ACTRN/NCT /ethics: 

    NCT03312842

    Scientific title: 

    OF ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY

    Summary of trial and patient characteristics

    Cancer Type All cancers
    Trial Type Treatment
    Phase Phase I Tumour Stream Solid Tumours
    Age Range 18 years to 75 years Cancer Stage Locally Recurrent or Locally Advanced, Metastatic or Widespread
    Sex Both Anticipated Start Date 2017-10-19
    Molecular Target Anticipated End Date 2021-03-01
    Cancer Type All cancers
    Trial Type Treatment
    Phase Phase I
    Age Range 18 years to 75 years
    Sex Both
    Molecular Target
    Tumour Stream Solid Tumours
    Cancer Stage Locally Recurrent or Locally Advanced, Metastatic or Widespread
    Anticipated Start Date 2017-10-19
    Anticipated End Date 2021-03-01

    Trial Summary

    OF ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY

    Lay Summary

    OF ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY

    Sponsor / Cooperative group

    Cstone Pharmaceuticals

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Ashford Cancer Centre Research Sue Yeend syeend@adelaidecancercentre.com.au 08 8292 2240 Dr Anna Mislang Recruiting